• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建模奥密克戎 BA.5 亚变体在新西兰的影响。

Modelling the impact of the Omicron BA.5 subvariant in New Zealand.

机构信息

Manaaki Whenua, Lincoln, New Zealand.

Mathematics and Statistics, University of Canterbury, Christchurch, New Zealand.

出版信息

J R Soc Interface. 2023 Feb;20(199):20220698. doi: 10.1098/rsif.2022.0698. Epub 2023 Feb 1.

DOI:10.1098/rsif.2022.0698
PMID:36722072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9890098/
Abstract

New Zealand experienced a wave of the Omicron variant of SARS-CoV-2 in early 2022, which occurred against a backdrop of high two-dose vaccination rates, ongoing roll-out of boosters and paediatric doses, and negligible levels of prior infection. New Omicron subvariants have subsequently emerged with a significant growth advantage over the previously dominant BA.2. We investigated a mathematical model that included waning of vaccine-derived and infection-derived immunity, as well as the impact of the BA.5 subvariant which began spreading in New Zealand in May 2022. The model was used to provide scenarios to the New Zealand Government with differing levels of BA.5 growth advantage, helping to inform policy response and healthcare system preparedness during the winter period. In all scenarios investigated, the projected peak in new infections during the BA.5 wave was smaller than in the first Omicron wave in March 2022. However, results indicated that the peak hospital occupancy was likely to be higher than in March 2022, primarily due to a shift in the age distribution of infections to older groups. We compare model results with subsequent epidemiological data and show that the model provided a good projection of cases, hospitalizations and deaths during the BA.5 wave.

摘要

2022 年初,新西兰经历了一波由 SARS-CoV-2 的奥密克戎变异株引起的疫情,当时该国的两剂疫苗接种率很高,加强针和儿科剂量的接种工作正在进行中,且先前的感染率可忽略不计。随后出现了新的奥密克戎亚变种,其相对于之前占主导地位的 BA.2 具有显著的增长优势。我们研究了一个数学模型,该模型考虑了疫苗衍生和感染衍生免疫的衰减,以及 2022 年 5 月在新西兰开始传播的 BA.5 亚变种的影响。该模型用于向新西兰政府提供具有不同 BA.5 增长优势水平的情景,以帮助在冬季期间为政策应对和医疗保健系统的准备提供信息。在所研究的所有情景中,BA.5 波期间新感染的预计峰值均低于 2022 年 3 月的第一波奥密克戎疫情。然而,结果表明,医院占用率的峰值可能高于 2022 年 3 月,主要是由于感染人群的年龄分布向老年群体转移。我们将模型结果与随后的流行病学数据进行了比较,并表明该模型很好地预测了 BA.5 波期间的病例、住院和死亡情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/352a74d0cf2c/rsif20220698f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/6acb05e91fd1/rsif20220698f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/aaa836346ad6/rsif20220698f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/352a74d0cf2c/rsif20220698f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/6acb05e91fd1/rsif20220698f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/aaa836346ad6/rsif20220698f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed74/9890098/352a74d0cf2c/rsif20220698f03.jpg

相似文献

1
Modelling the impact of the Omicron BA.5 subvariant in New Zealand.建模奥密克戎 BA.5 亚变体在新西兰的影响。
J R Soc Interface. 2023 Feb;20(199):20220698. doi: 10.1098/rsif.2022.0698. Epub 2023 Feb 1.
2
Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.奥密克戎变异株 SARS-CoV-2 在新西兰的感染动力学、免疫衰减和再感染建模。
Epidemics. 2022 Dec;41:100657. doi: 10.1016/j.epidem.2022.100657. Epub 2022 Nov 21.
3
Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.新英格兰地区估计 SARS-CoV-2 奥密克戎 BA.2 亚变种的严重程度。
JAMA Netw Open. 2022 Oct 3;5(10):e2238354. doi: 10.1001/jamanetworkopen.2022.38354.
4
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.丹麦全国性观察研究:与 SARS-CoV-2 奥密克戎亚变体 BA.2.86 和后代 JN.1 相关的相对疫苗保护、疾病严重程度和症状。
Lancet Infect Dis. 2024 Sep;24(9):964-973. doi: 10.1016/S1473-3099(24)00220-2. Epub 2024 May 15.
5
Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.在新西兰的一个初免人群中,第三剂 BNT162b2 疫苗对 SARS-CoV-2 奥密克戎变异株具有强大的免疫原性。
Vaccine. 2023 Aug 31;41(38):5535-5544. doi: 10.1016/j.vaccine.2023.07.051. Epub 2023 Jul 27.
6
An assessment of the potential impact of the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变异株在新西兰可能产生的影响的评估。
Infect Dis Model. 2022 Jun;7(2):94-105. doi: 10.1016/j.idm.2022.04.002. Epub 2022 Apr 9.
7
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.BNT162b2 和 CoronaVac 新冠疫苗对奥密克戎 BA.2 亚谱系引起的 SARS-CoV-2 无症状和有症状感染的有效性:一项前瞻性队列研究。
Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12.
8
BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.新加坡儿童和青少年中 BNT162b2 疫苗对奥密克戎的保护作用以及既往感染变异株和接种顺序的影响:一项基于人群的队列研究。
Lancet Child Adolesc Health. 2023 Jul;7(7):463-470. doi: 10.1016/S2352-4642(23)00101-3. Epub 2023 May 15.
9
Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.2021 年 8 月至 2022 年 3 月,英国青少年在先前感染和接种疫苗后对 delta(B.1.617.2)和 omicron(B.1.1.529)BA.1 和 BA.2 SARS-CoV-2 变异株的症状性感染的保护作用:一项全国性、观察性、基于检测的病例对照研究。
Lancet Infect Dis. 2023 Apr;23(4):435-444. doi: 10.1016/S1473-3099(22)00729-0. Epub 2022 Nov 24.
10
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.医护人员中,mRNA 疫苗接种与未接种者,初次感染奥密克戎(B.1.1.529)BA.1 或 前奥密克戎 SARS-CoV-2 对 BA.2 再感染的保护作用:一项病例对照研究。
Lancet Infect Dis. 2023 Jan;23(1):45-55. doi: 10.1016/S1473-3099(22)00578-3. Epub 2022 Sep 21.

引用本文的文献

1
Optimising Control Device Luring Strategies for Invasive Predator Control: A Modelling Approach.优化用于入侵捕食者控制的诱捕策略:一种建模方法。
Ecol Evol. 2024 Nov 28;14(12):e70604. doi: 10.1002/ece3.70604. eCollection 2024 Dec.
2
Quantifying age-specific household contacts in Aotearoa New Zealand for infectious disease modelling.为传染病建模量化新西兰奥塔哥地区特定年龄段的家庭接触情况。
R Soc Open Sci. 2024 Oct 2;11(10):240550. doi: 10.1098/rsos.240550. eCollection 2024 Oct.
3
Structured methods for parameter inference and uncertainty quantification for mechanistic models in the life sciences.

本文引用的文献

1
Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis.预测疫苗对 COVID-19 重症的长期有效性和对变异株的有效性:一项荟萃分析。
Nat Commun. 2023 Mar 24;14(1):1633. doi: 10.1038/s41467-023-37176-7.
2
Modelling the dynamics of infection, waning of immunity and re-infection with the Omicron variant of SARS-CoV-2 in Aotearoa New Zealand.奥密克戎变异株 SARS-CoV-2 在新西兰的感染动力学、免疫衰减和再感染建模。
Epidemics. 2022 Dec;41:100657. doi: 10.1016/j.epidem.2022.100657. Epub 2022 Nov 21.
3
Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border.
生命科学中用于机理模型参数推断和不确定性量化的结构化方法。
R Soc Open Sci. 2024 Aug 21;11(8):240733. doi: 10.1098/rsos.240733. eCollection 2024 Aug.
4
Jointly estimating epidemiological dynamics of Covid-19 from case and wastewater data in Aotearoa New Zealand.利用新西兰奥特亚罗瓦的病例和废水数据联合估计新冠疫情的流行病学动态。
Commun Med (Lond). 2024 Jul 15;4(1):143. doi: 10.1038/s43856-024-00570-3.
5
Near-term forecasting of Covid-19 cases and hospitalisations in Aotearoa New Zealand.新西兰奥克兰地区的新冠病例和住院人数的短期预测。
PLoS Comput Biol. 2024 Jan 8;20(1):e1011752. doi: 10.1371/journal.pcbi.1011752. eCollection 2024 Jan.
6
SARS-CoV-2 Omicron variants BA.4 and BA.5 dominated the fifth COVID-19 epidemiological wave in Mexico.SARS-CoV-2 奥密克戎变异株 BA.4 和 BA.5 主导了墨西哥第五波 COVID-19 疫情。
Microb Genom. 2023 Dec;9(12). doi: 10.1099/mgen.0.001120.
7
Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia.疫苗接种、加强针和封锁对法属波利尼西亚 COVID-19 浪潮的影响。
Nat Commun. 2023 Nov 13;14(1):7330. doi: 10.1038/s41467-023-43002-x.
8
SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.SARS-CoV-2 奥密克戎变异株:疾病负担、对疫苗有效性的影响以及对变异株适应性疫苗的需求。
Front Immunol. 2023 May 23;14:1130539. doi: 10.3389/fimmu.2023.1130539. eCollection 2023.
追踪奥克兰新西兰重新开放边境后 SARS-CoV-2 奥密克戎变异株的国际输入情况。
Nat Commun. 2022 Oct 29;13(1):6484. doi: 10.1038/s41467-022-34186-9.
4
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.BA.5 奥密克戎亚变体再感染风险、疫苗保护效力和感染严重程度:丹麦全国基于人群的研究。
Lancet Infect Dis. 2023 Feb;23(2):167-176. doi: 10.1016/S1473-3099(22)00595-3. Epub 2022 Oct 18.
5
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.既往感染严重急性呼吸综合征冠状病毒2对奥密克戎BA.4和BA.5亚变体的保护作用。
N Engl J Med. 2022 Oct 27;387(17):1620-1622. doi: 10.1056/NEJMc2209306. Epub 2022 Oct 5.
6
Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants.曾接触过新冠病毒既往变种的人群感染BA.5的风险。
N Engl J Med. 2022 Sep 8;387(10):953-954. doi: 10.1056/NEJMc2209479. Epub 2022 Aug 31.
7
Comparison of the 2021 COVID-19 roadmap projections against public health data in England.比较 2021 年 COVID-19 路线图预测与英格兰公共卫生数据。
Nat Commun. 2022 Aug 22;13(1):4924. doi: 10.1038/s41467-022-31991-0.
8
Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era.在奥密克戎时代模拟英格兰地区 SARS-CoV-2 传播的中期动态。
Nat Commun. 2022 Aug 19;13(1):4879. doi: 10.1038/s41467-022-32404-y.
9
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection.奥密克戎 BA.4/BA.5 逃避由 BA.1 感染引起的中和抗体免疫。
Nat Commun. 2022 Aug 10;13(1):4686. doi: 10.1038/s41467-022-32396-9.
10
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.奥密克戎 BA.4 和 BA.5 对疫苗和 BA.1 血清的抗体逃逸。
Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9.